Published Date: 08 Mar 2023
A new white paper from the American Foregut Society expands gastrointestinal tract (EGJ) classification, including axial hiatal hernia length, hiatal hernia opening diameter, ...
Read Full NewsAI is saving clinicians time, but the majority of healthcare professionals say training in the technology is inadequate, inconsistent or unavailable, a global survey...
The recent hantavirus outbreak underscores how urbanization, deforestation, and rodent reservoirs can converge to shape zoonotic risk.
Dr Maurie Markman discusses a PLCO trial analysis highlighting the stark association between consistent heavy drinking and increased colorectal cancer risk.
The short answer is yes. Dr F. Perry Wilson explains why he believes AI still has a role in radiology.
A medical oncologist seeks to use his computer science knowledge to make AI understandable to the medical community.
Dr Emil Lou breaks down practice-changing GI oncology data from ASCO 2026, including transformative survival updates in pancreatic and upper GI cancers.
As menopause has become more visible online, experts see both benefits and risks, from greater patient engagement to the spread of misinformation.
1.
Using AI, one can find cancer risk factors.
2.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
3.
FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC
4.
Does pollution cause cancer?
5.
Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.
1.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
2.
CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review
3.
Cancer Vaccines in Solid Tumors: Current Landscape, Mechanisms, and Clinical Implications
4.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
5.
Unveiling the Hidden Benefits of Lymphedema Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation